Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-225
Closed -$9.18K 203
2023
Q1
$9.18K Buy
225
+2
+0.9% +$86 0.01% 208
2022
Q4
$11.4K Buy
223
+2
+0.9% +$96 0.01% 204
2022
Q3
$10K Buy
221
+2
+0.9% +$97 0.01% 203
2022
Q2
$11K Buy
219
+2
+0.9% +$102 0.01% 218
2022
Q1
$11K Buy
217
+1
+0.5% +$52 0.01% 232
2021
Q4
$13K Buy
216
+2
+0.9% +$99 0.01% 211
2021
Q3
$9K Buy
214
+2
+0.9% +$89 0.01% 227
2021
Q2
$8K Buy
212
+2
+1% +$78 ﹤0.01% 230
2021
Q1
$8K Buy
210
+2
+1% +$71 0.01% 199
2020
Q4
$8K Sell
208
-9
-4% -$330 0.01% 150
2020
Q3
$8K Buy
217
+2
+0.9% +$70 0.01% 131
2020
Q2
$7K Buy
215
+2
+0.9% +$68 0.01% 151
2020
Q1
$7K Buy
213
+3
+1% +$102 ﹤0.01% 276
2019
Q4
$8K Buy
210
+1
+0.5% +$36 ﹤0.01% 275
2019
Q3
$7K Buy
209
+2
+1% +$73 ﹤0.01% 280
2019
Q2
$8K Buy
207
+3
+1% +$119 ﹤0.01% 307
2019
Q1
$8K Buy
204
+2
+1% +$80 ﹤0.01% 295
2018
Q4
$8K Buy
202
+1
+0.5% +$42 ﹤0.01% 275
2018
Q3
$8K Buy
201
+2
+1% +$77 ﹤0.01% 275
2018
Q2
$7K Buy
199
+1
+0.5% +$34 ﹤0.01% 281
2018
Q1
$7K Buy
198
+2
+1% +$69 ﹤0.01% 266
2017
Q4
$7K Buy
196
+2
+1% +$68 ﹤0.01% 244
2017
Q3
$7K Buy
+194
New +$6.24K ﹤0.01% 247

Other funds holding PFE

Fortis Advisors's PFE Position: Q2 2023 in Review

Fortis Advisors sold out of Pfizer (PFE) in Q2 2023, closing a stake of 225 shares — an estimated $9.18K sold.

Fortis Advisors first reported a position in PFE in Q3 2017 and held it in 23 quarters. The position peaked at $13K in Q4 2021. 3,041 funds tracked by Wall St. Rank hold PFE as of Q2 2023.

  • Fortis Advisors reported no remaining Pfizer position as of Q2 2023 after selling out during the quarter.
  • Fortis Advisors sold 225 Pfizer shares in Q2 2023, an estimated $9.18K.
  • Fortis Advisors first reported a position in Pfizer in Q3 2017 and held it in 23 quarters.
  • Fortis Advisors's Pfizer position peaked at $13K in Q4 2021.
  • 3,041 funds tracked by Wall St. Rank held Pfizer as of Q2 2023.

Based on Fortis Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.